AUTHOR=Lichtblau Mona , Berlier Charlotte , Saxer Stéphanie , Carta Arcangelo F. , Mayer Laura , Groth Alexandra , Bader Patrick R. , Schneider Simon R. , Furian Michael , Schwarz Esther I. , Swenson Erik R. , Bloch Konrad E. , Ulrich Silvia 

TITLE=Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial

JOURNAL=Frontiers in Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.681473

DOI=10.3389/fmed.2021.681473

ISSN=2296-858X

ABSTRACT=<p><bold>Aims:</bold> To test the acute hemodynamic effect of acetazolamide in patients with pulmonary hypertension (PH) under ambient air and hypoxia.</p><p><bold>Methods:</bold> Patients with pulmonary arterial or chronic thromboembolic PH (PAH/CTEPH) undergoing right heart catheterization were included in this randomized, placebo-controlled, double-blinded, crossover trial. The main outcome, pulmonary vascular resistance (PVR), further hemodynamics, blood- and cerebral oxygenation were measured 1 h after intravenous administration of 500 mg acetazolamide or placebo-saline on ambient air (normoxia) and at the end of breathing hypoxic gas (F<sub>I</sub>O<sub>2</sub> 0.15, hypoxia) for 15 min.</p><p><bold>Results:</bold> 24 PH-patients, 71% men, mean ± SD age 59 ± 14 years, BMI 28 ± 5 kg/m<sup>2</sup>, PVR 4.7 ± 2.1 WU participated. Mean PVR after acetazolamide vs. placebo was 5.5 ± 3.0 vs. 5.3 ± 3.0 WU; mean difference (95% CI) 0.2 (−0.2–0.6, <italic>p</italic> = 0.341). Heart rate was higher after acetazolamide (79 ± 12 vs. 77 ± 11 bpm, <italic>p</italic> = 0.026), pH was lower (7.40 ± 0.02 vs. 7.42 ± 0.03, <italic>p</italic> = 0.002) but PaCO<sub>2</sub> and PaO<sub>2</sub> remained unchanged while cerebral tissue oxygenation increased (71 ± 6 vs. 69 ± 6%, <italic>p</italic> = 0.017). In acute hypoxia, acetazolamide decreased PVR by 0.4 WU (0.0–0.9, <italic>p</italic> = 0.046) while PaO<sub>2</sub> and PaCO<sub>2</sub> were not changed. No adverse effects occurred.</p><p><bold>Conclusions:</bold> In patients with PAH/CTEPH, i.v. acetazolamide did not change pulmonary hemodynamics compared to placebo after 1 hour in normoxia but it reduced PVR after subsequent acute exposure to hypoxia. Our findings in normoxia do not suggest a direct acute pulmonary vasodilator effect of acetazolamide. The reduction of PVR during hypoxia requires further corroboration. Whether acetazolamide improves PH when given over a prolonged period by stimulating ventilation, increasing oxygenation, and/or altering vascular inflammation and remodeling remains to be investigated.</p>